Published in:

01-12-2025 | Inflammatory Bowel Disease

Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD

Authors: Monica Dzwonkowski, Janak Bahirwani, Samantha Rollins, Alicia Muratore, Vikram Christian, Yecheskel Schneider

Published in: Current Gastroenterology Reports | Issue 1/2025

Abstract

Purpose of Review

Inflammatory bowel disease (IBD) can cause significant psychological, physical, and economic burdens on patients and healthcare systems. Studies show over one-fifth of patients will seek nontraditional methods of treatment for managing their symptoms. Understanding the benefits - and potential harms - of these therapies is important to provide holistic and evidence-based care to our IBD patients.

Recent Findings

In this review, we present several studied herbal therapies for the management of both Crohn’s disease and ulcerative colitis. These include cannabinoids, Tripterygium wilfordii, Chios mastic gum, Boswellia serrata, Indigo Naturalis, curcumin, resveratrol, and Zingiber officinale. While these herbal remedies have been shown to have anti-inflammatory effects and positive outcomes in IBD patients, larger scale studies are lacking and the use may be limited by bioavailability, lack of standardization of formulations, and adverse reactions.

Summary

In reviewing the literature, we discuss the current data available including benefits, adverse reactions, and considerations for use surrounding several of the more common herbal remedies used for IBD.

Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(1):17–30. https://doi.org/10.1016/S2468-1253(19)30333-4.CrossRef

Langhorst J, Wulfert H, Lauche R, et al. Systematic review of complementary and alternative Medicine treatments in Inflammatory Bowel diseases. J Crohns Colitis. 2015;9(1):86–106. https://doi.org/10.1093/ecco-jcc/jju007.CrossRefPubMed

Holleran G, Scaldaferri F, Gasbarrini A, Currò D. Herbal medicinal products for inflammatory bowel disease: a focus on those assessed in double-blind randomised controlled trials. Phytother Res. 2020;34(1):77–93. https://doi.org/10.1002/ptr.6517.CrossRefPubMed

Doeve BH, van de Meeberg MM, van Schaik FDM, Fidder HH. A systematic review with Meta-analysis of the efficacy of Cannabis and cannabinoids for Inflammatory Bowel Disease: what can we learn from Randomized and Nonrandomized studies? J Clin Gastroenterol. 2021;55(9):798–809. https://doi.org/10.1097/MCG.0000000000001393.CrossRefPubMed

DiPatrizio NV. Endocannabinoids in the gut. Cannabis Cannabinoid Res. 2016;1(1):67–77. https://doi.org/10.1089/can.2016.0001.CrossRefPubMedPubMedCentral

Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–106. https://doi.org/10.1136/gutjnl-2019-318484.CrossRefPubMed

Sexton KA, Walker JR, Targownik LE, et al. The inflammatory bowel Disease Symptom Inventory: a patient-report scale for Research and clinical application. Inflamm Bowel Dis. 2019;25(8):1277–90. https://doi.org/10.1093/ibd/izz038.CrossRefPubMedPubMedCentral

DEA to Hold Hearing on the Rescheduling of Marijuana. Accessed December 6. 2024. https://www.dea.gov/stories/2024/2024-11/2024-11-26/dea-hold-hearing-rescheduling-marijuana

Velez-Santiago A, Alvarez-Torres E, Martinez-Rodriguez R, et al. A survey of Cannabis Use among patients with inflammatory bowel disease (IBD). Int J Environ Res Public Health. 2023;20(6):5129. https://doi.org/10.3390/ijerph20065129.CrossRefPubMedPubMedCentral

10.

Lal S, Prasad N, Ryan M, et al. Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011;23(10):891–6. https://doi.org/10.1097/MEG.0b013e328349bb4c.CrossRefPubMed

11.

Dalavaye N, Erridge S, Nicholas M, et al. The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry. Expert Rev Gastroenterol Hepatol. 2023;17(1):85–98. https://doi.org/10.1080/17474124.2022.2161046.CrossRefPubMed

12.

Storr M, Devlin S, Kaplan GG, Panaccione R, Andrews CN. Cannabis Use provides Symptom Relief in patients with inflammatory bowel disease but is Associated with worse Disease Prognosis in patients with Crohn’s Disease. Inflamm Bowel Dis. 2014;20(3):472–80. https://doi.org/10.1097/01.MIB.0000440982.79036.d6.CrossRefPubMed

13.

Weiss A, Friedenberg F. Patterns of cannabis use in patients with inflammatory bowel disease: a population based analysis. Drug Alcohol Depend. 2015;156:84–9. https://doi.org/10.1016/j.drugalcdep.2015.08.035.CrossRefPubMed

14.

Borra V, Borra N, Bondi G, et al. Is dependent cannabis use in adult hospitalizations with inflammatory bowel disease associated with major adverse cardiovascular and cerebrovascular events? Insights from National Inpatient Sample Analysis. Curr Med Res Opin. 2024;40(4):605–11. https://doi.org/10.1080/03007995.2024.2321328.CrossRefPubMed

15.

Naftali T, Lev LB, Yablecovitch D, Half E, Konikoff FM. Treatment of Crohn’s disease with cannabis: an observational study. Isr Med Assoc J IMAJ. 2011;13(8):455–8.PubMed

16.

Glickman D, Dalessio S, Raup-Konsavage WM, Vrana KE, Coates MD. The impact of Cannabis Use on Clinical outcomes in Inflammatory Bowel Disease: a Population-based Longitudinal Cohort Study. Inflamm Bowel Dis. 2024;30(7):1055–61. https://doi.org/10.1093/ibd/izad151.CrossRefPubMed

17.

Lahat A, Lang A, Ben-Horin S. Impact of cannabis treatment on the quality of life, weight and clinical disease activity in inflammatory bowel disease patients: a pilot prospective study. Digestion. 2012;85(1):1–8. https://doi.org/10.1159/000332079.CrossRefPubMed

18.

Naftali T, Bar-Lev Schleider L, Dotan I, Lansky EP, Sklerovsky Benjaminov F, Konikoff FM. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2013;11(10):1276–e12801. https://doi.org/10.1016/j.cgh.2013.04.034.CrossRef

19.

Naftali T, Bar-Lev Schleider L, Almog S, Meiri D, Konikoff FM. Oral CBD-rich Cannabis induces clinical but not endoscopic response in patients with Crohn’s Disease, a Randomised Controlled Trial. J Crohns Colitis. 2021;15(11):1799–806. https://doi.org/10.1093/ecco-jcc/jjab069.CrossRefPubMed

20.

Naftali T, Mechulam R, Marii A, et al. Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s Disease, a Randomized Controlled Trial. Dig Dis Sci. 2017;62(6):1615–20. https://doi.org/10.1007/s10620-017-4540-z.CrossRefPubMed

21.

Irving P, Iqbal T, Nwokolo C, et al. PTH-056 trial to assess cannabidiol in the symptomatic treatment of ulcerative colitis. Gut. 2015;64(Suppl 1):A430–430. https://doi.org/10.1136/gutjnl-2015-309861.944.CrossRef

22.

Naftali T, Bar-Lev Schleider L, Scklerovsky Benjaminov F, Konikoff FM, Matalon ST, Ringel Y. Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: a randomized controlled trial. PLoS ONE. 2021;16(2):e0246871. https://doi.org/10.1371/journal.pone.0246871.CrossRefPubMedPubMedCentral

23.

Buckley MC, Kumar A, Swaminath A. Inflammatory bowel Disease and Cannabis: a practical Approach for clinicians. Adv Ther. 2021;38(7):4152–61. https://doi.org/10.1007/s12325-021-01805-8.CrossRefPubMedPubMedCentral

24.

Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5(1):1–8. https://doi.org/10.1097/ADM.0b013e31820c23fa.CrossRefPubMedPubMedCentral

25.

Cahill SP, Lunn SE, Diaz P, Page JE. Evaluation of patient reported Safety and Efficacy of Cannabis from a survey of Medical Cannabis patients in Canada. Front Public Health. 2021;9:626853. https://doi.org/10.3389/fpubh.2021.626853.CrossRefPubMedPubMedCentral

26.

Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primer. 2021;7(1):16. https://doi.org/10.1038/s41572-021-00247-4.CrossRef

27.

Zhang J, Huang Q, Zhao R, Ma Z. A network pharmacology study on the Tripteryguim Wilfordii Hook for treatment of Crohn’s disease. BMC Complement Med Ther. 2020;20:95. https://doi.org/10.1186/s12906-020-02885-9.CrossRefPubMedPubMedCentral

28.

Ren J, Wu W, Liao N, et al. Prevention of postoperative recurrence of Crohn’s disease: Tripterygium Wilfordii polyglycoside versus mesalazine. J Int Med Res. 2013;41(1):176–87. https://doi.org/10.1177/0300060512474744.CrossRefPubMed

29.

Alimentary P. & Therapeutics| Pharmacology Journal| Wiley Online Library. Accessed December 6, 2024. https://onlinelibrary.wiley.com/doi/full/10.1111/apt.12464?

30.

Tao Q, song, Ren J an, Ji Z ling, Li Jsheng, Wang X bo, Jiang X. hua. [Maintenance effect of polyglycosides of Tripterygium wilfordii on remission in postoperative Crohn disease]. Zhonghua Wei Chang Wai Ke Za Zhi Chin J Gastrointest Surg. 2009;12(5):491–493.

31.

Sun J, Shen X, Dong J, et al. Tripterygium wilfordii hook F as maintenance treatment for Crohn’s Disease. Am J Med Sci. 2015;350(5):345–51. https://doi.org/10.1097/MAJ.0000000000000591.CrossRefPubMed

32.

Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, Andrikopoulos NK. Chios mastic treatment of patients with active Crohn’s disease. World J Gastroenterol WJG. 2007;13(5):748–53. https://doi.org/10.3748/wjg.v13.i5.748.CrossRefPubMed

33.

Kakdiya R, Jha DK, Choudhury A, Jena A, Sharma V. Indigo Naturalis (Qing dai) for inflammatory bowel disease: a systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2024;48(1):102250. https://doi.org/10.1016/j.clinre.2023.102250.CrossRefPubMed

34.

Papada E, Gioxari A, Amerikanou C, et al. Regulation of faecal biomarkers in inflammatory bowel disease patients treated with oral mastiha (Pistacia lentiscus) supplement: a double-blind and placebo-controlled randomised trial. Phytother Res PTR. 2019;33(2):360–9. https://doi.org/10.1002/ptr.6229.CrossRefPubMed

35.

Triantafyllidi A, Xanthos T, Papalois A, Triantafillidis JK. Herbal and plant therapy in patients with inflammatory bowel disease. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2015;28(2):210–20.

36.

Iyengar P, Godoy-Brewer G, Maniyar I, et al. Herbal Medicines for the treatment of active Ulcerative Colitis: a systematic review and Meta-analysis. Nutrients. 2024;16(7):934. https://doi.org/10.3390/nu16070934.CrossRefPubMedPubMedCentral

37.

Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R. [Therapy of active Crohn disease with Boswellia serrata extract H 15]. Z Gastroenterol. 2001;39(1):11–7. https://doi.org/10.1055/s-2001-10708.CrossRefPubMed

38.

Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2(1):37–43.PubMed

39.

Naganuma M, Sugimoto S, Suzuki H, et al. Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. J Gastroenterol. 2019;54(10):891–6. https://doi.org/10.1007/s00535-019-01591-9.CrossRefPubMed

40.

Kim HA, Suh HR, Kang B, Choe BH. Crohn’s and Colitis Association in DaeguGyeongbuk (CCAiD). Acute pancreatitis associated with indigo naturalis in pediatric severe Crohn’s disease. Intest Res. 2019;17(1):144–8. https://doi.org/10.5217/ir.2018.00104.CrossRefPubMed

41.

Matsuno Y, Torisu T, Umeno J, et al. One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study. Intest Res. 2022;20(2):260–8. https://doi.org/10.5217/ir.2021.00124.CrossRefPubMedPubMedCentral

42.

Naganuma M, Sugimoto S, Mitsuyama K, et al. Efficacy of Indigo Naturalis in a Multicenter Randomized Controlled Trial of patients with Ulcerative Colitis. Gastroenterology. 2018;154(4):935–47. https://doi.org/10.1053/j.gastro.2017.11.024.CrossRefPubMed

43.

Naganuma M, Sugimoto S, Fukuda T, et al. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study. J Gastroenterol. 2020;55(2):169–80. https://doi.org/10.1007/s00535-019-01625-2.CrossRefPubMed

44.

Uchiyama K, Takami S, Suzuki H, et al. Efficacy and safety of short-term therapy with indigo naturalis for ulcerative colitis: an investigator-initiated multicenter double-blind clinical trial. PLoS ONE. 2020;15(11):e0241337. https://doi.org/10.1371/journal.pone.0241337.CrossRefPubMedPubMedCentral

45.

Wang Y, Tang Q, Duan P, Yang L. Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis. Immunopharmacol Immunotoxicol. 2018;40(6):476–82. https://doi.org/10.1080/08923973.2018.1469145.CrossRefPubMed

46.

Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2006;4(12):1502–6. https://doi.org/10.1016/j.cgh.2006.08.008.CrossRef

47.

Singla V, Pratap Mouli V, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study. J Crohns Colitis. 2014;8(3):208–14. https://doi.org/10.1016/j.crohns.2013.08.006.CrossRefPubMed

48.

Lang A, Salomon N, Wu JCY, et al. Curcumin in Combination with Mesalamine induces remission in patients with mild-to-moderate Ulcerative Colitis in a Randomized Controlled Trial. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2015;13(8):1444–e14491. https://doi.org/10.1016/j.cgh.2015.02.019.CrossRef

49.

Masoodi M, Mahdiabadi MA, Mokhtare M, et al. The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self-reported well-being: a randomized double-blind controlled trial. J Cell Biochem. 2018;119(11):9552–9. https://doi.org/10.1002/jcb.27273.CrossRefPubMed

50.

Gowd V, Kanika null, Jori C, et al. Resveratrol and resveratrol nano-delivery systems in the treatment of inflammatory bowel disease. J Nutr Biochem. 2022;109:109101. https://doi.org/10.1016/j.jnutbio.2022.109101.CrossRefPubMed

51.

Gu Y, Lou Y, Zhou Z, et al. Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1411566. https://doi.org/10.3389/fphar.2024.1411566.CrossRefPubMedPubMedCentral

52.

Giang J, Lan X, Crichton M, Marx W, Marshall S. Efficacy and safety of biophenol-rich nutraceuticals in adults with inflammatory gastrointestinal diseases or irritable bowel syndrome: a systematic literature review and meta-analysis. Nutr Diet J Dietit Assoc Aust. 2022;79(1):76–93. https://doi.org/10.1111/1747-0080.12672.CrossRef

53.

Samsami-Kor M, Daryani NE, Asl PR, Hekmatdoost A. Anti-inflammatory effects of Resveratrol in patients with Ulcerative Colitis: a Randomized, Double-Blind, placebo-controlled pilot study. Arch Med Res. 2015;46(4):280–5. https://doi.org/10.1016/j.arcmed.2015.05.005.CrossRefPubMed

54.

Samsamikor M, Daryani NE, Asl PR, Hekmatdoost A. Resveratrol Supplementation and Oxidative/Anti-Oxidative status in patients with Ulcerative Colitis: a Randomized, Double-Blind, placebo-controlled pilot study. Arch Med Res. 2016;47(4):304–9. https://doi.org/10.1016/j.arcmed.2016.07.003.CrossRefPubMed

55.

Erol Doğan Ö, Karaca Çelik KE, Baş M, Alan EH, Çağın YF. Effects of Mediterranean Diet, Curcumin, and resveratrol on mild-to-moderate active Ulcerative Colitis: a Multicenter Randomized Clinical Trial. Nutrients. 2024;16(10):1504. https://doi.org/10.3390/nu16101504.CrossRefPubMedPubMedCentral

56.

Ballester P, Cerdá B, Arcusa R, Marhuenda J, Yamedjeu K, Zafrilla P. Effect of Ginger on Inflammatory diseases. Mol Basel Switz. 2022;27(21):7223. https://doi.org/10.3390/molecules27217223.CrossRef

57.

El-Abhar HS, Hammad LNA, Gawad HSA. Modulating effect of ginger extract on rats with ulcerative colitis. J Ethnopharmacol. 2008;118(3):367–72. https://doi.org/10.1016/j.jep.2008.04.026.CrossRefPubMed

58.

Nikkhah-Bodaghi M, Maleki I, Agah S, Hekmatdoost A. Zingiber officinale and oxidative stress in patients with ulcerative colitis: a randomized, placebo-controlled, clinical trial. Complement Ther Med. 2019;43:1–6. https://doi.org/10.1016/j.ctim.2018.12.021.CrossRefPubMed

Title: Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD
Authors: Monica Dzwonkowski
Janak Bahirwani
Samantha Rollins
Alicia Muratore
Vikram Christian
Yecheskel Schneider
Publication date: 01-12-2025
Publisher: Springer US
Keywords: Inflammatory Bowel Disease
Crohn's Disease
Ulcerative Colitis
Published in: Current Gastroenterology Reports / Issue 1/2025
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-025-00960-0

Rumination Syndrome, Supragastric Belching, and Abdominophrenic Dyssynergia: How to Diagnose and Treat?

Biofeedback

The nuances of SIBO breath testing

Free for a limited time
Diagnostics in Gastroenterology
Review

Non-celiac enteropathies

Success Rates for Endoscopic Placement of Post-Pyloric Nasoenteric Tube Underperform Expectations

Nutrition

The Neuroimmune Axis in Gastrointestinal Disorders – An Underrecognized Problem

Respiratory Microbiota

The Gut in Critical Illness

Nutrition

Keynote series | Spotlight on managing health in obesity

Obesity
Video Series

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman

Prof. Jonette Keri

Developed by: Springer Medicine

Watch now

Women’s health knowledge hub

Menopause
Clinical Collection

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Live
Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital

Prof. Ronald F. van Vollenhoven

Developed by: Springer Medicine

Keynote series | Spotlight on managing health in obesity

Springer Medicine

Selected Use of Complementary and Alternative Medicine (CAM) Agents in IBD

Abstract

Purpose of Review

Recent Findings

Summary

Other articles of this Issue 1/2025

Rumination Syndrome, Supragastric Belching, and Abdominophrenic Dyssynergia: How to Diagnose and Treat?

The nuances of SIBO breath testing

Non-celiac enteropathies

Success Rates for Endoscopic Placement of Post-Pyloric Nasoenteric Tube Underperform Expectations

The Neuroimmune Axis in Gastrointestinal Disorders – An Underrecognized Problem

The Gut in Critical Illness

Keynote series | Spotlight on managing health in obesity

Women’s health knowledge hub

Keynote webinar | Spotlight on advances in lupus

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content